Biomarker Menu
Biomarker Menu

Explore Our Biomarker Menu

Including 400+ Biomarker Offerings for a Range of Disease States

Return to Biomarker Menu

Biomarker: CHOP (total)

Search for Biomarkers


CHOP (total)



Experienced Running

Biological or Clinical Significance:

C/EBP homologous protein (CHOP), also known as growth arrest- and DNA damage-inducible gene 153 (GADD153) is a 29 kDa transcription factor that mediates one of the three arms of unfolded protein response (UPR) adaptation to endoplasmic reticulum stressors. CHOP/GADD153 plays a key role in ER stress-mediated apoptosis and in diseases including diabetes, brain ischemia and neurodegenerative disease.

Since induction of CHOP is involved in the development of various diseases, CHOP-targeted therapies may be useful for these diseases. For instance, suppression of CHOP by RNA interference, decoy oligodeoxynucleotides or drug inhibitors could have a significant therapeutic potential to modulate type I diabetes, brain ischemia and others. On the other hand, overexpression of CHOP may represent a new class of anticancer therapy. Since induction of BiP has been observed in a variety of tumor cells, overexpression of CHOP directed by the BiP promoter may be used as a highly specific therapy for cancer. Further studies on CHOP-mediated apoptosis will provide a basis for new therapeutic approaches to diseases associated with ER stress.


Speak to a Scientist

    What would you like to discuss?

    With whom will we be speaking?

    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

    Yes I confirm that I am over the age of 16 and I consent to communications from BioAgilytix.

    biomarker services


    See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.

    Explore our services

    case studies

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.

    Read our case studies